Twinbeech Capital LP Novavax Inc Transaction History

Twinbeech Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$5.76 - $12.48 $164,154 - $355,667	28,499 New	28,499 $197,000
Q2 2022 Aug 15, 2022	BUY	$36.28 - $75.29 $1.12 Million - $2.33 Million	30,907 New	30,907 $1.59 Million
Q1 2022 May 16, 2022	SELL	$69.73 - $142.9 $1.65 Million - $3.39 Million	-23,703 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $3.19 Million - $5.17 Million	23,703 New	23,703 $3.39 Million
Q2 2021 Aug 16, 2021	SELL	$121.0 - $257.67 $880,880 - $1.88 Million	-7,280 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$112.98 - $319.93 $822,494 - $2.33 Million	7,280 New	7,280 $1.32 Million

292

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $630M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.